Floatz logo

Vyxeos

Acute Myeloid Leukemia With FLT3/ITD Mutation

H. Lee Moffitt Cancer Center and Research InstitutePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Acute Myeloid Leukemia With FLT3/ITD Mutation cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3BB
Azacitidine
French Innovative Leukemia Organisation
Phase 2BB
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BB
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3BB
Quizartinib
M.D. Anderson Cancer Center
Phase 2BB

View all 23 →

Same molecule, other indications

Vyxeos is also rated in:

myelodysplastic syndromeDormant
B
Indicative ·
57 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
56 / 100
View asset →
childhood acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →